Bead-based ELISA for validation of ovarian cancer early detection markers

被引:127
作者
Scholler, N
Crawford, M
Sato, A
Drescher, CW
O'Briant, KC
Kiviat, N
Anderson, GL
Urban, N
机构
[1] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98195 USA
[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Womens Hlth Initiat Clin Coordinating Ctr, Seattle, WA 98195 USA
[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Translat Outcomes Res Lab, Seattle, WA 98195 USA
关键词
D O I
10.1158/1078-0432.CCR-05-2007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Efforts to validate ovarian cancer early detection biomarkers with immunoassays are challenged by the limited specimen volumes available. We sought to develop a specimen-efficient assay to measure CA125 in serum, assess its reproducibility, validity, and performance, and test its potential for multiplexing and combining with human epididymis protein 4 (HE4), a promising novel ovarian cancer marker. Experimental Design: Four pairs of commercially available anti-CA125 antibodies and one pair of anti-HE4 antibodies were evaluated for accuracy in measuring known concentrations of antigen on a bead-based platform. The two best pairs were further assessed for reproducibility, validity, and the ability to discriminate between blinded serum samples obtained from ovarian cancer cases (n = 66) and women without ovarian cancer (n = 125). Results: Suitability for use in a bead-based assay varied across CA125 antibody pairs. Two CA125 bead-based assays were highly reproducible (overall correlations between replicates >= 0.95; coefficients of variation < 0.2) and strongly correlated with the research standard CA125II RIA (correlations >= 0.9). Their ability to distinguish ovarian cancer cases from non-cases based on receiver operating characteristic analyses (area under the curve, AUC, of 0.85 and 0.84) was close to that of the CA125II RIA (AUC, 0.87). The HE4 bead-based assay showed lower reproducibility but yielded an AUC of 0.89 in receiver operating characteristics analysis. Multiplexing was not possible but a composite marker including CA125 and HE4 achieved an AUC of 0.91. Conclusion: Optimization procedures yielded two bead-based assays for CA125 that perform comparably to the standard CA125II RIA, which could be combined with an HE4 bead-based assay to improve diagnostic performance, and requires only 15 mu L of sample each.
引用
收藏
页码:2117 / 2124
页数:8
相关论文
共 35 条
[1]   Implementation of the Women's Health Initiative Study Design [J].
Anderson, GL ;
Manson, J ;
Wallace, R ;
Lund, B ;
Hall, D ;
Davis, S ;
Shumaker, S ;
Wang, CY ;
Stein, E ;
Prentice, RL .
ANNALS OF EPIDEMIOLOGY, 2003, 13 (09) :S5-S17
[2]   AREA ABOVE ORDINAL DOMINANCE GRAPH AND AREA BELOW RECEIVER OPERATING CHARACTERISTIC GRAPH [J].
BAMBER, D .
JOURNAL OF MATHEMATICAL PSYCHOLOGY, 1975, 12 (04) :387-415
[3]   Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer [J].
Baron, AT ;
Boardman, CH ;
Lafky, JM ;
Rademaker, A ;
Liu, DC ;
Fishman, DA ;
Podratz, KC ;
Maihle, NJ .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) :306-318
[4]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[5]   CA 125: The past and the future [J].
Bast, RC ;
Xu, FJ ;
Yu, YH ;
Barnhill, S ;
Zhang, Z ;
Mills, GB .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187
[6]  
Bast Robert C Jr, 2002, Cancer Treat Res, V107, P61
[7]   COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH [J].
DELONG, ER ;
DELONG, DM ;
CLARKEPEARSON, DI .
BIOMETRICS, 1988, 44 (03) :837-845
[8]   Early detection of familial ovarian cancer [J].
Dorum, A ;
Kristensen, GB ;
Abeler, VM ;
Trope, CG ;
Moller, P .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (10) :1645-1651
[9]   Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas [J].
Drapkin, R ;
von Horsten, HH ;
Lin, YF ;
Mok, SC ;
Crum, CP ;
Welch, WR ;
Hecht, JL .
CANCER RESEARCH, 2005, 65 (06) :2162-2169
[10]  
Eagle, 1997, Oncologist, V2, P324